Boisvert, Isabelle
Rivera, Samantha Cruz
Smith-Merry, Jennifer
Molony-Oates, Barbara
Kecman, Emily
Hughes, Sarah E.
Funding for this research was provided by:
UK SPINE programme & Birmingham Health Partners’ Centre for Regulatory Science & Innovation
Article History
Received: 18 April 2024
Accepted: 10 September 2024
First Online: 27 September 2024
Declarations
:
: Ethics approval was granted by the University of Birmingham Research Ethics Committee (ERN_22-0712) and The University of Sydney Human Research Ethics Committee (2022/491). All participants gave their informed, electronic consent prior to the workshops. No defining details are reported to maintain participants’ anonymity.
: All participants consented for anonymised quotes to be used in published research.
: IB is a named researcher on initiatives funded by Cochlear Ltd at other organisations, but her research initiatives, publications and views are independent of any commercial funding. SEH receives funding from Anthony Nolan, the National Institute for Health and Care Research (NIHR) Applied Research Collaboration (ARC), West Midlands and the NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics at the University of Birmingham and the Research for Patient Benefit Programme. SEH declares personal fees from Cochlear, Pfizer, CIS Oncology, Astra Zeneca, Rinri Therapeutics, and Aparito outside the submitted work. The views expressed in this article are those of the authors. BMO's involvement in this piece of work is in a personal capacity and is not as a representative of the Health Research Authority, UK.